Mepolizumab Beneficial in COPD With Eosinophilic Phenotype

This article originally appeared here.
Share this content:
Mepolizumab Beneficial in COPD With Eosinophilic Phenotype
Mepolizumab Beneficial in COPD With Eosinophilic Phenotype

TUESDAY, Sept. 12, 2017 (HealthDay News) -- Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from mepolizumab, a monoclonal antibody directed against interleukin-5, according to a study published online Sept. 12 in the New England Journal of Medicine to coincide with the European Respiratory Society International Congress, held from Sept. 9 to 13 in Milan.

Ian D. Pavord, M.B.B.S., D.M., from the University of Oxford in the United Kingdom, and colleagues performed two phase 3, randomized trials comparing mepolizumab (100 mg in METREX and 100 or 300 mg in METREO) with placebo in patients with COPD with a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy.

The researchers found that the mean annual rate of moderate or severe exacerbations in the modified intention-to-treat population with an eosinophilic phenotype was 1.40 and 1.71 per year in the mepolizumab and placebo groups in METREX (rate ratio, 0.82; 95 percent confidence interval, 0.68 to 0.98; adjusted P = 0.04). The mean annual rate of moderate or severe exacerbations was 1.19 and 1.27 per year in the 100-mg and 300-mg mepolizumab groups, and 1.49 per year in the placebo group in METREO (rate ratios, 0.80 [95 percent confidence interval, 0.65 to 0.98; adjusted P = 0.07] and 0.86 [95 percent confidence interval, 0.70 to 1.05; adjusted P = 0.14], respectively).

"This finding suggests that eosinophilic airway inflammation contributes to COPD exacerbations," the authors write.

The study was partially funded by GlaxoSmithKline, the manufacturer of mepolizumab.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »